Prelude Therapeutics Incorporated announced multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude's CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for SMARCA2 degrader compound, PRT3789.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.795 USD | -4.89% | -6.76% | -11.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.12% | 219M | |
+25.64% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.06% | 12.09B | |
+0.19% | 11.88B | |
-1.24% | 11.8B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference